On December 7 Roche announced the FDA approval of its triplet of programmed...
- EMA issues positive opinion on biomarker for Parkinson’s trials
- New drugs and therapeutic options help the immune system fight cancer
- May’s top news stories
- US biosimilar setbacks highlight difficulty of cost-effective development
- POINT trial may increase clopidogrel use in secondary ischemic stroke prevention
Roche’s Tecentriq triplet versus Keytruda + chemotherapy: an Uphill Struggle?
On December 7 Roche announced the FDA approval of its triplet of programmed death-ligand 1 (PD-L1) inhibitor Tecentriq (atezolizumab) + vascular endothelial growth factor (VEGF) inhibitor Avastin (bevacizumab) + chemotherapy (paclitaxel + carboplatin) in the highly prized indication of untreated non-squamous non-small cell lung cancer (NSCLC).
Quick and Flexible Elemental Screening with Omnian
Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.
Vitrakvi (larotrectinib) for Advanced Solid Tumours with NTRK Gene Fusion
Vitrakvi® (larotrectinib) is an oral tyrosine kinase (TRK) inhibitor indicated for the treatment of advanced solid tumours in adult and paediatric patients with neurotrophic receptor tyrosine kinase (NTRK) gene fusion.
Xospata (gilteritinib) for Acute Myeloid Leukaemia with FLT3 Mutation
Xospata® (gilteritinib) is a feline McDonough sarcoma (FMS) like tyrosine kinase 3 (FLT3) inhibitor indicated for the treatment of relapsed or refractory acute myeloid leukaemia (AML) with FLT3 mutation in adult patients. It is one of the first FDA-approved FLT3-targeting therapies for the indication.
Gamifant (emapalumab-lzsg) for Primary Haemophagocytic Lymphohistiocytosis
Gamifant® (emapalumab-lzsg) is an interferon gamma (IFNγ) blocking antibody indicated for the treatment of primary haemophagocytic lymphohistiocytosis (HLH) in paediatric and adult patients.
Tradjenta Indicated for the Treatment of Type II Diabetes
Linagliptin (BI-1356), which is being marketed under the trade name Tradjenta®, is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor drug for the treatment of type 2 diabetes.
Blincyto® (blinatumomab) for the Treatment of B-cell Precursor Acute Lymphoblastic Leukaemia
Blincyto® (blinatumomab) is a monoclonal antibody indicated as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children.
Lorbrena (lorlatinib) for ALK-Positive Metastatic Non-Small Cell Lung Cancer
Lorbrena® (lorlatinib) is an anaplastic lymphoma kinase (ALK) inhibitor indicated as a second or third-line treatment of advanced non-small cell lung cancer (NSCLC). The drug was discovered and developed by Pfizer.
Dupixent (dupilumab) for the Treatment of Atopic Dermatitis
Dupixent (dupilumab) is an investigational drug being developed by Sanofi and Regeneron as a treatment for moderate to severe atopic dermatitis in adult patients.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.